Clinical trials: Human Cancers
Human Papilloma Virus, Squamous Cell Carcinoma
De-Escalation Therapy for Human Papillomavirus Negative Disease
This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the…
- Conditions
- Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma
- Trial name
- DEPEND (NCT03944915)
- Testing
- Carboplatin, Paclitaxel, Nivolumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Solid Tumor, Adult
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
The main purpose of this first-in-human study of GEN1056, is to evaluate safety. In addition, the study will determine the recommended dose and frequency for subsequent clinical studies and will assess the preliminary anti-tumor…
- Trial name
- NCT05586321
- Testing
- GEN1056
- Where
- 7 sites in Georgia, Moldova and 1 more
- Volunteers
- 26 people
- Sponsor
- Genmab
Neoplasms, Triple-Negative Breast Cancer
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02078752
- Testing
- PF-06647263
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo in participants with HER2-positive and PD-L1-positive LABC or…
- Trial name
- KATE3 (NCT04740918)
- Testing
- Trastuzumab Emtansine, Atezolizumab
- Where
- 51 sites in United States, Australia and 17 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Cancer
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
The goal of this study is to visualize biodistribution of a PET tracer called [18F]F-AraG through time in healthy human volunteers.
- Trial name
- NCT02323893
- Testing
- [18F]F-AraG
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- CellSight Technologies, Inc.
Hepatocellular Carcinoma in Hepatitis C Virus Infected Patients
Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC.
Prospective study to calculated the incidence of hepatocellular carcinoma in hepatitis C virus infected patients after stem cell therapy.
- Trial name
- NCT01729221
- Where
- Egypt
- Volunteers
- 280 people
- Sponsor
- Cairo University
Hepatocellular Carcinoma
Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)
Hepatocellular carcinoma(HCC) is a high malignancy cancer which progress rapidly , and the rates of morbidity and mortality is very high in China.
- Trial name
- NCT03208335
- Testing
- recombinant human endostatin
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Locally Advanced Cervical Cancer, Prognostic Biomarker
Evaluation of Persistent Infection by Oncogenic Human Papillomavirus (HPV) in Patients Treated for Cervical Carcinoma and Its Relation to Prognostic Factors
Cervical cancer is strongly associated with HPV infection, yet current post-treatment follow-up relies on cytology and imaging, which have limited accuracy, particularly after radiotherapy.
- Trial name
- ANIHTA (NCT07600515)
- Volunteers
- 100 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Neoplasms, Breast
Lapatinib and Bevacizumab for Metastatic Breast Cancer
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
- Trial name
- NCT00444535
- Testing
- lapatinib, bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment caused by these HBV-TCR redirected T-cells in…
- Trial name
- SAFE-T-HBV (NCT04745403)
- Testing
- mRNA HBV/TCR T-cells
- Where
- Singapore
- Volunteers
- 10 people
- Sponsor
- Lion TCR Pte. Ltd.
Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
- Trial name
- NCT04272203
- Testing
- ABBV-184
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- AbbVie
Genito Urinary Cancer, Bladder Cancer
Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers
The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor cells (HSPCs) to reconstitute a match human immune system in our PDX model.
- Conditions
- Genito Urinary Cancer, Bladder Cancer, Kidney Cancer, Prostate Cancer
- Trial name
- Immune PDX (NCT03134027)
- Testing
- Bone marrow biopsy, Tumor biopsy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Cervical Cancer, DNA Methylation
Cervical Cytology DNA Methylation for Cervical Cancer Screening
Cervical cancer represents one of the foremost causes of cancer-related morbidity and mortality among women worldwide. Given the current limitations, such as the low specificity of human papillomavirus (HPV) testing and the…
- Conditions
- Cervical Cancer, DNA Methylation, Cytology, Human Papillomavirus Infection
- Trial name
- NCT06557954
- Testing
- human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m)
- Where
- China
- Volunteers
- 30,000 people
- Sponsor
- Lei Li
Hepatocellular Carcinoma
Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic Patients
The goal of this study is Utility of abbrevational magnetic resonance imaging as a screening tool for hepatocellular carcinoma in cirrhotic patients.
- Trial name
- NCT05716620
- Testing
- MRI
- Where
- India
- Volunteers
- 380 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Polycystic Ovary Syndrome
Response of VEGF and AT-II to HCG in PCOS
This research is to investigate the response of vascular active factors, vascular endothelial growth factor (VEGF) and angiotensin-Ⅱ (AT-Ⅱ) to ovary stimulation during 24h in patients with polycystic ovary syndrome…
- Trial name
- NCT02265861
- Testing
- HCG
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Colorectal Neoplasms
Colonoscopic Removal of Aberrant Crypt Foci: a Prospective, Randomized, Blinded Trial
We hypothesized that aberrant crypt foci (ACF) are precursors of colon cancer; their prevention would correlate with cancer risk and their elimination would reduce that risk.
- Trial name
- NCT00623883
- Testing
- Surgical removal of ACF, Colonoscopic evaluation only
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- National Naval Medical Center
Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma
Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
This phase I trial tests the safety, side effects, and best dose of decitabine in combination with standard of care surgery, radiation, and/or chemotherapy and the effectiveness of the combination in treating patients with head…
- Conditions
- Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
- Trial name
- NCT06997094
- Testing
- Biospecimen Collection, Chemotherapy, Decitabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mayo Clinic
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune…
- Trial name
- NCT05662020
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
- Where
- China
- Volunteers
- 2,750 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Leukemia, Lymphoma
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation.
- Conditions
- Leukemia, Lymphoma, Oral Complications
- Trial name
- NCT00004061
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, HER2 Positive Breast Cancer
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
The purpose of this study is to see if IPI-504 in combination with trastuzamab is an effective treatment in HER2 positive metastatic breast cancer
- Conditions
- Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
- Trial name
- NCT00817362
- Testing
- IPI-504, Trastuzumab
- Where
- 11 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.